Author: PharmaSignal News Desk

Keytruda subcutaneous launch by Merck aims to offset sales decline as original loses patent protection, with analysts projecting market impact.

Ascletis weight loss drug ASC47 shows over 56% greater body weight reduction when combined with semaglutide in obesity treatment.

Trump tariffs pharmaceuticals, exempting companies with US sites, aim to boost domestic production and impact global market dynamics.

GSK CEO Luke Miels is set to lead the company into a pivotal growth phase starting January 2026.

Crystalys gout drug debuts with $205M funding and partial rights in multiple Asian countries.

Genmab Merus acquisition for $8 billion enhances its oncology portfolio with innovative therapies like Petosemtamab.

Bristol Myers Squibb launches Sotyktu at an 86% discount, reducing the price to $950 for cash-paying U.S. patients.

Trump drug price deadline prompts pharma firms to announce initiatives, impacting U.S. market with new models.

Glenmark Hengrui licensing deal secures $1 billion, granting exclusive rights and impacting the pharmaceutical market.

Successful drug launches need realistic forecasts and market preparation, says Jason O’Neill, highlighting common pitfalls in new product launches.